[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Günay C, Atalar H, Kaygusuz G, Yildiz Y, Sağlik Y: [Alveolar soft part sarcoma of the extremities: an evaluation of four cases]. Acta Orthop Traumatol Turc; 2007 Aug-Oct;41(4):326-31
Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alveolar soft part sarcoma of the extremities: an evaluation of four cases].
  • We presented four patients (3 women, 1 man; mean age 40 years; range 20 to 56 years) who had alveolar soft part sarcoma in the left arm, right elbow, right tibia, and left thigh, respectively.
  • Two patients had lung metastasis at the time of diagnosis.
  • T1- and T2-weighted magnetic resonance images of all the patients showed a soft tissue lesion with hyperintense signal changes and heterogeneous contrast enhancement.
  • All the patients received chemotherapy.
  • Two patients with involvement of the left arm and right elbow died within three years after diagnosis.
  • One patient with involvement of the left thigh developed lung and brain metastases at the end of postoperative eight years.
  • [MeSH-major] Sarcoma, Alveolar Soft Part / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Arm. Diagnosis, Differential. Elbow. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Thigh. Tibia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180565.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


2. Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM: Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer; 2006 Apr 15;106(8):1776-84
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
  • BACKGROUND: Extensive and mutilating surgery is often required for locally advanced soft tissue sarcoma (STS) of the limb.
  • ILPs were performed at mild hyperthermic conditions with 1-4 mg of TNF and 10-13 mg/L limb-volume melphalan (M) for leg and arm perfusions, respectively.
  • The procedure could be performed safely, with a perioperative mortality of 0.5% in all patients with no age limit (median age, 54 yrs; range, 12-91).
  • CONCLUSION: TNF+M-based ILP can provide limb salvage in a significant percentage of patients with locally advanced STS and has therefore gained a permanent place in the multimodality treatment of STS.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Extremities. Limb Salvage. Melphalan / administration & dosage. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prognosis. Recombinant Proteins / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16541435.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


3. O'Donnell TM, Devitt AT, Kutty S, Fogarty EE: Recurrent congenital haemangiopericytoma in a child. J Bone Joint Surg Br; 2001 Mar;83(2):269-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A five-day-old boy was referred with a soft-tissue mass in his right upper arm.
  • Open biopsy confirmed the diagnosis of congenital haemangiopericytoma.
  • After MRI and selective angiography, excision biopsy was carried out, but no adjuvant therapy was administered.
  • Congenital haemangiopericytoma is a rare cause of a soft-tissue mass in children.
  • The treatment is controversial, but most centres recommend the use of adjuvant chemotherapy, combined with complete excision.
  • We recommend treatment with doxorubicin.
  • [MeSH-major] Hemangiopericytoma / congenital. Soft Tissue Neoplasms / congenital
  • [MeSH-minor] Arm. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284579.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, van Geel AN, Ezzat A, Santoro A, Oosterhuis JW, van Glabbeke M, Kirkpatrick A, Verweij J, E.O.R.T.C. Soft Tissue Bone Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group/Canadian Sarcoma Group: A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer; 2001 Jun;37(9):1096-103
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
  • The aim of this study was to examine the strategy, feasibility and outcome of neo-adjuvant chemotherapy, with doxorubicin and ifosfamide, in adult patients with 'high-risk' soft-tissue sarcomas.
  • Patients with 'high-risk' soft-tissue sarcomas, defined as tumours > or =8 cm of any grade, or grade II/III tumours <8 cm, or grade II/III locally recurrent tumours, or grade II/III tumours with inadequate surgery performed in the previous 6 weeks and therefore requiring further surgery, were randomised between either surgery alone or three cycles of 3-weekly doxorubicin 50 mg/m(2) intravenous (i.v.) bolus and ifosfamide 5 g/m(2) (24 h infusion) before surgery.
  • The type of surgery had to be planned at randomisation.
  • If chemotherapy was given, surgery had to be performed within 21 days after the last chemotherapy.
  • 150 patients were entered into the study and 134 were eligible, 67 in each arm.
  • The most frequent side-effects of chemotherapy were alopecia, nausea and vomiting (95%), and leucocytopenia (32%).
  • One patient died of neutropenic fever after the first cycle of chemotherapy.
  • Chemotherapy did not interfere with planned surgery and did not affect postoperative wound healing.
  • At a median follow-up of 7.3 years, the 5 year disease-free survival is estimated at 52% for the no chemotherapy and 56% for the chemotherapy arm (standard error: 7%) (P=0.3548).
  • Neo-adjuvant-chemotherapy with doxorubicin and ifosfamide at these doses and with this schedule was feasible and did not compromise subsequent treatment, surgery with or without radiotherapy.
  • Although not powered to draw definitive conclusions on benefit, but with an at least 7 year median follow-up, the results render it less likely that major survival benefits will be achieved with this type of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy / methods. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Preoperative Care / methods. Risk Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378339.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


5. Murray PM: Soft tissue sarcoma of the upper extremity. Hand Clin; 2004 Aug;20(3):325-33, vii
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma of the upper extremity.
  • Soft tissue sarcomas of the upper extremities are rare and hand surgeons typically encounter only one or two undiagnosed soft tissue sarcomas during their careers.
  • It is incumbent on the physician to review repeatedly the characteristics of these tumors and remain suspicious, because these lesions typically are misdiagnosed and treatment is delayed.
  • The most common soft tissue sarcomas of the upper extremity are the epithelioid sarcoma, synovial cell sarcoma, and malignant fibrous histiocytoma.
  • Limb salvage surgery is the treatment of choice for soft tissue sarcomas to preserve upper extremity function.
  • Following wide tumor resection, adjuvant therapies such as chemotherapy, external beam radiation therapy, and brachytherapy may lessen local recurrence rates, but their effect on overall survival remains unclear.
  • [MeSH-major] Sarcoma. Soft Tissue Neoplasms
  • [MeSH-minor] Arm. Biopsy. Chemotherapy, Adjuvant. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / surgery. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Histiocytoma, Benign Fibrous / mortality. Histiocytoma, Benign Fibrous / pathology. Humans. Liposarcoma / pathology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Sarcoma, Clear Cell / diagnosis. Sarcoma, Synovial / diagnosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15275691.001).
  • [ISSN] 0749-0712
  • [Journal-full-title] Hand clinics
  • [ISO-abbreviation] Hand Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


6. Picci P: Adjuvant chemotherapy for extremity soft-tissue sarcomas in adults. Curr Oncol Rep; 2000 Nov;2(6):502-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for extremity soft-tissue sarcomas in adults.
  • Due to the peculiar characteristics of sarcomas, which include classification problems, heterogeneity of presentation, and treatment, no consensus exists regarding the best strategies to follow.
  • In particular, there is no consensus on the use of chemotherapy in localized high-grade sarcomas, with contradictory results reported in medical literature.
  • Both studies confirm the advantage of adjuvant chemotherapy in disease-free and overall surivall in very select groups of high-grade sarcomas of the extremities.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Arm / pathology. Arm / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Leg / pathology. Leg / surgery. Neoplasm Staging. Patient Selection. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1999 Jan;32(1):32-7 [9917750.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):57-69 [10030416.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):504-14 [9344316.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):352-9 [10516382.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1438-43 [9552049.001]
  • [Cites] Acta Orthop Scand Suppl. 1999 Jun;285:50-7 [10429623.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1418-26 [9193334.001]
  • [Cites] J Clin Oncol. 1986 Apr;4(4):552-8 [3514804.001]
  • [Cites] Oncology. 1999;56(1):13-23 [9885372.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2772-80 [10561352.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):328-48 [10516380.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):646-52 [9053489.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):349-51 [10516381.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Sep-Oct;16(5):397-406 [10505315.001]
  • [Cites] Arch Surg. 1999 Aug;134(8):856-61; discussion 861-2 [10443809.001]
  • [Cites] J Surg Oncol. 1999 Jul;71(3):155-61 [10404131.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1219 [10561182.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1121-34 [8203453.001]
  • [Cites] Semin Surg Oncol. 1999 Jul-Aug;17(1):47-51 [10402637.001]
  • (PMID = 11122885.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


7. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK: A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer; 2005 Apr 1;103(7):1431-8
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arm A included patients with osteogenic sarcoma, Ewing sarcoma, and rhabdomyosarcoma.
  • Arm B accrued patients with other types of soft tissue sarcomas.
  • Patients were not allowed to have received previous chemotherapy for metastatic disease.
  • Arm A had low accrual and was closed.
  • One confirmed partial response among 21 evaluable patients was observed on Arm B in a patient with leiomyosarcoma.
  • CONCLUSIONS: Bortezomib has minimal activity in soft tissue sarcoma as a single agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Boronic Acids / therapeutic use. Proteasome Inhibitors. Pyrazines / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bortezomib. Drug Administration Schedule. Fatigue / chemically induced. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nervous System Diseases / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15739208.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM17105; United States / NCI NIH HHS / CA / P01-CA47179
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


8. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM: The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer; 2006 Jan 1;106(1):156-62
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Both patients with soft tissue sarcoma (STS) and patients with melanoma have limited treatment possibilities once the tumor has metastasized systemically.
  • Isolated limb perfusion (ILP) has proven to be an excellent, local, limb-saving treatment option in patients with locally advanced extremity tumors.
  • In this study, the authors investigated the palliative value of the ILP procedure to avoid amputation in patients who had Stage IV STS and melanoma.
  • Limb salvage was achieved in 36 of 37 patients, with 1 patient undergoing amputation due to treatment toxicity.
  • CONCLUSIONS: TNF-based ILP is an excellent procedure that provided tumor control and limb salvage for the short survival of patients with metastasized, very bulky, limb-threatening tumors of the extremity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / therapeutic use. Palliative Care. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation. Arm. Female. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323177.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


9. Zawitkowska-Klaczyńska J, Katski K, Woźniak M, Kowalczyk JR: Characteristics and outcome of children with primary soft tissue sarcomas of extremities. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):169-74
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of children with primary soft tissue sarcomas of extremities.
  • OBJECTIVES: To determine the characteristics and outcome or patients with primary soft tissue sarcomas of extremities in children.
  • MATERIAL AND METHODS: Thirty-six patients treated for soft tissues sarcomas were enrolled into the study.
  • Features analysed: the incidence of soft tissues sarcoma of extremities, the time from first clinical symptoms to making the diagnosis, the primary site of tumour; histopathologic type of tumour, stage of disease, methods and results of the treatment.
  • RESULTS: The time From first symptoms to making the diagnosis was 5.4 months (mean).
  • The site of the tumour was the femur in 6 patients, arm in 3, knee in 1.
  • Histopathologic types: synovial sarcoma in 4 patients, malignant haemangiopericytoma in 2, rhabdomyosarcoma in 2, sarcoma myogenes in 1, primitive neuroectodermal tumour in l.
  • Patients underwent treatment according to the soft tissue sarcoma protocols.
  • Results of treatment: first complete remission was observed in 7 patients; second complete remission in 1, one patient is on postoperative treatment.
  • Combined treatment achieves full remission in the majority of patients with soft tissues sarcomas localized within the limbs.
  • 2. In patients with large tumours (>5 cm) the treatment should to be started with inductive chemotherapy, and the surgery should be postponed.
  • 3. Early excision of the tumour should be considered in cases of small tumours (< 5 cm), when resection with wide margin of healthy tissues is possible, without deteriorating the function of the limb or cosmetic damage.
  • [MeSH-major] Arm. Leg. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiopericytoma / diagnosis. Hemangiopericytoma / therapy. Humans. Incidence. Male. Myosarcoma / diagnosis. Myosarcoma / therapy. Neoplasm Staging. Neuroectodermal Tumors / diagnosis. Neuroectodermal Tumors / therapy. Poland / epidemiology. Retrospective Studies. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738590.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


10. Papanastassiou I, Ioannou M, Magoulas D, Lalos S, Athanassiou AE, Ziras N, Thanopoulou E, Demertzis N: Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma. J BUON; 2009 Jul-Sep;14(3):507-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma.
  • A 26 year-old male was referred to our unit because of a stage III soft tissue sarcoma in the shoulder girdle-axillary area and reduced forearm-distal arm strength.
  • The patient received adjuvant chemotherapy (ifosfamide/mesna, adriamycin, and dacarbazine/MAID) and finally radiation therapy (RT; 6500 cGy total dose).
  • In stage III soft tissue sarcomas, especially in proximity with major nerve/arterial bundles, a multimodality approach is mandatory; chemoembolization is very effective in shrinking the tumor and defining its margins so as to make feasible a LSS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Embolization, Therapeutic. Limb Salvage. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810146.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


11. Fayette J, Penel N, Chevreau C, Blay JY, Cupissol D, Thyss A, Guillemet C, Rios M, Rolland F, Fargeot P, Bay JO, Mathoulin-Pelissier S, Coindre JM, Bui-Nguyen B: Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs; 2009 Oct;27(5):482-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
  • Multidrug chemotherapy increases responses in advanced soft tissues sarcoma.
  • From 1994 to 1997, 162 patients were randomized in a phase III study to the conventional drug combination (6 cycles of MAID: 60, 7,500, 900 mg/m(2) for doxorubicin, ifosfamide and dacarbazine respectively), or at doses 20-33% higher per cycle (5 cycles of intensified MAID for similar cumulative doses) with systematic G-CSF.
  • Only grade 3-4 thrombocytopenia and anemia were significantly higher in intensified arm.
  • Treatment with intensified MAID did not improve response rate neither survival and cannot be recommended for advanced or metastatic soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leiomyosarcoma / drug therapy. Liposarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Dacarbazine / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):706-11 [16496406.001]
  • [Cites] Oncology. 2006;71(1-2):32-9 [17344669.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2755-63 [17602081.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Am J Clin Oncol. 1999 Jun;22(3):267-72 [10362334.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1197-205 [18224666.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3144-50 [17634494.001]
  • [Cites] Biometrics. 1987 Mar;43(1):213-23 [3567306.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2629-36 [7595717.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] N Engl J Med. 1988 Sep 8;319(10):593-8 [3045544.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):576-84 [15659504.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):364-99 [17442230.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • (PMID = 19148579.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


12. Lans TE, Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM: Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol; 2005 May;12(5):406-11
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
  • BACKGROUND: Recurrent extremity soft tissue sarcoma (STS) in a previously operated and irradiated area can usually be managed only by amputation.
  • Because radiotherapy is known to destroy vasculature, we wanted to evaluate retrospectively whether the outcome of ILP in patients with radiotherapy for their primary tumor nonetheless showed a benefit from TNF treatment.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Limb Salvage / methods. Melphalan / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arm. Combined Modality Therapy. Female. Humans. Leg. Male. Middle Aged

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915375.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


13. Spugnini EP, Baldi A, Vincenzi B, Bongiorni F, Bellelli C, Citro G, Porrello A: Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol; 2007 Feb;59(3):375-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model.
  • Feline soft tissue sarcomas are spontaneous, rapidly growing, and aggressive neoplasms that mimic their human counterpart.
  • The purpose of this study was to evaluate the feasibility and efficacy of electrochemotherapy (ECT) in an adjuvant fashion for the treatment of feline sarcomas, and the possibility of repeated treatments in the case of recurrence.
  • Feline patients recruited in the ECT study were enrolled in a microscopic arm (39 patients) or a macroscopic arm (19 patients) on the basis of their tumor status (absence or presence of gross disease).
  • Patients received local injection of bleomycin followed by bursts of eight biphasic pulses at a voltage of 1,300 V/cm for postoperative and of 800 V/cm for intraoperative treatments.
  • The median time to recurrence was 4 months for cats treated with surgery alone, 19 months for the postoperative cohort, and 12 months for the intraoperative group.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bleomycin / therapeutic use. Cat Diseases / drug therapy. Disease Models, Animal. Electrochemotherapy / veterinary. Fibrosarcoma / veterinary. Soft Tissue Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Combined Modality Therapy. Disease-Free Survival. Intraoperative Care. Neoplasm Recurrence, Local. Postoperative Care. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807731.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin
  •  go-up   go-down


14. Vuoristo MS, Hahka-Kemppinen M, Parvinen LM, Pyrhönen S, Seppä H, Korpela M, Kellokumpu-Lehtinen P: Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res; 2005 Aug;15(4):291-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
  • The treatment arms were: A, DTIC plus nIFN-alpha; B, BOLD plus nIFN-alpha; C, DTIC plus rIFN-alpha2b; D, BOLD plus rIFN-alpha2b.
  • The response rates were 8% (2/25) in arm A, 13% (4/31) in arm B, 12% (3/25) in arm C and 24% (6/25) in arm D.
  • All of the eight complete responses occurred in patients with soft tissue and/or lung metastases and the BOLD regimens produced six of them.
  • There were no significant differences in survival (arm A, 11.1 months; arm B, 9.8 months; arm C, 9.1 months; arm D, 7.5 months; P=0.62).
  • Patients with soft tissue or lung metastases may achieve more complete responses with BOLD regimens.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interferon Type I / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / therapeutic use. Dacarbazine / administration & dosage. Dacarbazine / therapeutic use. Female. Humans. Lomustine / administration & dosage. Lomustine / therapeutic use. Male. Middle Aged. Neoplasm Metastasis. Recombinant Proteins. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034308.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon Type I; 0 / Interferon-alpha; 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; BOLD protocol
  •  go-up   go-down


15. Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM: Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol; 2005 Jun;12(6):473-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg.
  • BACKGROUND: Treatment for extremity soft tissue sarcoma (STS) has shifted in recent years from amputation to local wide excision combined with irradiation.
  • To avoid amputations, isolated limb perfusion (ILP) with tumor necrosis factor and melphalan is an attractive treatment option for patients with multiple extremity sarcomas.
  • All ILPs were performed under mild hyperthermic conditions by using 1 to 4 mg of tumor necrosis factor and 10 to 13 mg/L of limb volume for leg and arm perfusions, respectively.
  • The toxicity of the procedure was mild to moderate in almost all cases; no treatment-related amputation had to be performed.
  • The time to local recurrence was 29 months and differed significantly between multiple primary and multiple recurrent STS.
  • Because this treatment option provides excellent local control, it should be considered before an amputation is planned.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Limb Salvage. Neoplasms, Second Primary / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amputation. Arm / pathology. Disease Progression. Female. Humans. Hyperthermia, Induced. Leg / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864484.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Fayette J, Coquard IR, Alberti L, Boyle H, Méeus P, Decouvelaere AV, Thiesse P, Sunyach MP, Ranchère D, Blay JY: ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol; 2006 Jul;18(4):347-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ET-743: a novel agent with activity in soft-tissue sarcomas.
  • In the clinical setting, after failure of standard treatment, ET-743 at 1.5 mg/m2 in 24 h continuous infusion every 21 days yielded an overall response rate close to 8% and stabilization rates of 30-40%, some lasting beyond 3 years.
  • In a randomized Phase II study testing weekly ET-743 with treatment every 3 weeks, an improved progression-free survival rate was observed in the 3-weekly arm; the results of the follow-up Phase III trial should be available at the American Society of Clinical Oncology meeting of 2006.
  • SUMMARY: ET-743 is a novel active drug for sarcoma which yields prolonged disease-free survival in subsets of patients.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / therapeutic use. Sarcoma / drug therapy. Tetrahydroisoquinolines / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. DNA / chemistry. DNA Repair. Disease-Free Survival. Humans. Models, Chemical. Neoplasm Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721129.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; 9007-49-2 / DNA
  • [Number-of-references] 62
  •  go-up   go-down


17. Bonvalot S, Rimareix F, Paumier A, Roberti E, Bouzaiene H, Le Péchoux C: [What is new in the local approach of limb sarcomas and desmoid tumours?]. Cancer Radiother; 2010 Oct;14(6-7):455-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Actualisation de la stratégie thérapeutique locorégionale dans les sarcomes des tissus mous et les tumeurs desmoïdes des membres.
  • The treatment of soft tissue sarcomas of limbs should be discussed within an experienced multimodality team.
  • Surgical resection remains the cornerstone of therapy for localized disease and achieves a five years overall survival around 75% and a local recurrence rate as low as 10% in the best series.
  • In complex cases, neo-adjuvant treatments may be used such as systemic chemotherapy, isolated limb perfusion, or radiotherapy to achieve an optimal conservative approach.
  • Molecular genetics of sarcomas and quality of margins are essential to guide diagnosis and therapeutic selection.
  • In case of marginal or incomplete resection, a new enlarged surgical resection should always be discussed before administration of any adjuvant treatments.
  • Many retrospective studies and two randomized studies (one of adjuvant brachytherapy and one of external beam radiotherapy) have shown that adjuvant radiotherapy after complete surgery significantly reduces the risk of local recurrence in extremity soft tissue sarcomas.
  • The risk of surgical complications is higher in the preoperative arm and the risk of late sequelae is higher in the postoperative arm.
  • Presently, the role of systematic first-line invasive treatment (including surgery and/or radiotherapy) of desmoids is debated.
  • Additional study of the molecular determinants of desmoid behaviour is needed to guide treatment.
  • [MeSH-major] Extremities / surgery. Fibromatosis, Aggressive / surgery. Radiotherapy, Adjuvant. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Amputation. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Diagnostic Imaging / methods. Humans. Neoadjuvant Therapy. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Patient Care Team. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Reconstructive Surgical Procedures. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier SAS.
  • (PMID = 20797892.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


18. Torigoe T, Yazawa Y, Takagi T, Terakado A, Kurosawa H: Extraskeletal osteosarcoma in Japan: multiinstitutional study of 20 patients from the Japanese Musculoskeletal Oncology Group. J Orthop Sci; 2007 Sep;12(5):424-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unlike osteosarcoma of the bone, the efficacy of chemotherapy for extraskeletal osteosarcoma has not been established yet.
  • Six lesions were located in the thigh, four in the chest, four in the buttocks, three in the upper arm, and others.
  • Altogether, 15 patients received chemotherapy, of whom 11 had evaluable responses as follows: complete response in none, partial response in 5 patients, and no change or progressive disease in 6 patients, with a response rate of 45%.
  • CONCLUSIONS: Among the patients with extraskeletal osteosarcoma, both the 5-year survival rate and the chemotherapy response rate tended to improve in this study in comparison to the findings published in previous reports.
  • As a result, we believe that treatment regimens that include systemic chemotherapy may be able to improve the prognosis in patients with extraskeletal osteosarcoma.
  • [MeSH-major] Osteosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Japan / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909926.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


19. Grünhagen DJ, de Wilt JH, Verhoef C, van Geel AN, Eggermont AM: TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur J Surg Oncol; 2005 Oct;31(8):912-6
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoid tumours are soft tissue sarcomas with local aggressive behaviour and a high rate of local recurrence after treatment.
  • As isolated limb perfusion (ILP) with TNF and melphalan has proven to be extremely effective in the treatment of soft tissue sarcoma, we studied its potential in locally advanced extremity desmoid tumours.
  • Local surgical therapy with preservation of limb function was impossible in all patients due to large or multifocal tumours, multiple recurrences or extensive previous treatment.
  • Perfusions were performed with 4-3mg TNF and 10-13 mg/l limb volume melphalan form leg and arm perfusions, respectively.
  • Local control was obtained after 10/12 ILPs and in the other two patients through repeat ILP and systemic chemotherapy, thus leading to an overall local control rate of 100%.
  • CONCLUSION: ILP is a very effective treatment option in the multimodality treatment of limb desmoid tumours.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Dermoid Cyst / drug therapy. Lower Extremity / pathology. Melphalan / administration & dosage. Soft Tissue Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage. Upper Extremity / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Female. Humans. Limb Salvage. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prospective Studies. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098709.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


20. Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fátima Dias Gaui M, Reyes DO, Jassem J, Barton C, Button P, Hersberger V, Torres AA: Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol; 2010 Feb 20;28(6):976-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer.
  • PATIENTS AND METHODS Patients with HER2-positive locally advanced or metastatic breast cancer were randomly assigned to H (8 mg/kg loading; 6 mg/kg every 3 weeks) plus T (75 mg/m(2) in HTX arm, 100 mg/m(2) in HT arm, every 3 weeks) with or without X (950 mg/m(2) twice per day on days 1 to 14 every 3 weeks).
  • Treatment-related grade 3 hand-foot syndrome (17% v < 1%) and grade 3/4 diarrhea (11% v 4%) occurred more commonly with HTX than HT.
  • One case of congestive heart failure occurred in each arm.
  • CONCLUSION HTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Receptor, ErbB-2 / metabolism. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. In Situ Hybridization, Fluorescence. International Agencies. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Taxoids / administration & dosage. Trastuzumab. Treatment Outcome. Young Adult


21. Altmann S, Lenz-Scharf O, Schneider W: [Therapeutic options for aggressive fibromatosis]. Handchir Mikrochir Plast Chir; 2008 Apr;40(2):88-93
Genetic Alliance. consumer health - Fibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options for aggressive fibromatosis].
  • INTRODUCTION: Aggressive fibromatosis, e.g., desmoid tumour, is a rare neoplasm of the connective tissue with local infiltrative growth.
  • Because of the high recurrence rates and destruction of the surrounding tissue, these tumours are classified as semi-malignant.
  • Radical surgical treatment with tumour excision accompanied by radiotherapy is the current standard therapy that can be supplemented by pharmacological treatment in a few cases.
  • PATIENTS AND METHOD: We report on 9 patients (5 males and 4 females) with surgical therapy for aggressive fibromatosis.
  • The neoplasm was located on the extremities in 7 cases (4 x upper extremity, 3 x lower extremity), one tumour was situated in the chin and one in the rectus abdominis muscle.
  • In these cases, an adjuvant radiotherapy with 25 x 2 Gy was started postoperatively after the accomplished wound healing.
  • Treatment with chemotherapeutic agents was not necessary.
  • DISCUSSION: Aggressive fibromatosis is a semimalignant neoplasm of the connective tissue with an extremely high recurrence rate.
  • Therapy of choice is the radical surgical resection.
  • Pharmacological treatment should be considered for patients with unsuccessful local therapy.
  • [MeSH-major] Fibromatosis, Aggressive / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Arm. Chin. Female. Follow-Up Studies. Humans. Leg. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant. Rectus Abdominis. Surgical Flaps. Time Factors

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437666.001).
  • [ISSN] 0722-1819
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Noorda EM, Vrouenraets BC, Nieweg OE, Van Coevorden F, Kroon BB: Isolated limb perfusion: what is the evidence for its use? Ann Surg Oncol; 2004 Sep;11(9):837-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Following the principles of Evidence-Based Medicine, we reviewed the best available evidence for isolated limb perfusion (ILP) for melanoma and soft tissue sarcoma (STS) of the limb.
  • Therapeutic M-ILP, with or without tumor-necrosis factor alpha and interferon gamma (T(I)M-ILP), seems indicated in unresectable melanoma (level 3 to 4 evidence).
  • A comparison of level 3 to 4 studies on ILP and other neoadjuvant treatment modalities for unresectable STS shows that ILP results in the highest limb salvage rate with the lowest complication rate.
  • ILP seems the most effective limb sparing, neoadjuvant treatment modality when compared with other neoadjuvant treatment options for unresectable STS of the limb (level 3 to 4 evidence), although randomized studies are lacking.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Skin Neoplasms / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Arm. Evidence-Based Medicine. Humans. Leg. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313738.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down






Advertisement